Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 65.87 Bil Enterprise Value: 59.05 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 08:00PM GMT
Release Date Price: MXN876.8
Matthew Thomas Holt
JP Morgan Chase & Co, Research Division - Analyst

Everyone, my name is Matthew Holt, and I'm part of the JPM Biotech equity research team. It's my pleasure to introduce our next presenting company, Ultragenyx Pharmaceuticals. Presenting for Ultragenyx today will be the CEO and President, Emil Kakkis. And please note that following the presentation -- or it's actually at 1:30, there will be a breakout session in the Olympic room, which is to the left.

So with that, I'll hand it over to you.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Thanks very much and good afternoon, everyone. I'm happy to be here to give you an update on Ultragenyx. This is our legal warning. Company now, I think, 2020, just coming close to 10 years from founding, is really positioned for significant value of growth. We have strong revenue drivers, with the Crysvita franchise, which is growing at exceptional rate in addition to other products, in fact, we expect to have 3 products and 4 indications approved later this year

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot